Table 1.
Clinical characteristics.
| Patient number | 80 |
| Biopsy number | 133 |
| Age at biopsy [years] | 50 (19–69) |
| Age at Ltx [years] | 47 (2–68) |
| Including pediatric Ltx ≤ 18 years [number (%)] | 4/80 (5%) |
| Time since Ltx [months] | 25 (3–298) |
| Male gender | 49/80 (62%) |
| Indication for Ltx | |
| Autoimmune liver diseases | 36% |
| Acute liver failure | 15% |
| Alcoholic cirrhosis | 11% |
| Hepatocellular carcinoma | 8% |
| Viral hepatitis | 8% |
| Cryptogenic | 8% |
| others | 14% |
| Including retransplantation | 12.5% |
| Immunosuppression at biopsy | |
| CNI | 51% Tacrolimus |
| 46% Cyclosporine A | |
| mTOR | 2% Everolimus |
| 2% Sirolimus | |
| Mycophenolate | 75% |
| Prednisolone | 85% |
| Mono/double/triple immunosuppression | 2/33/65% |
| Biochemistry | |
| AST [times ULN] | 0.74 (0.29–1.91) |
| ALT [times ULN] | 0.47 (0.13–1.97) |
| ALP [times ULN] | 0.65 (0.19–1.54) |
| gGT [times ULN] | 0.53 (0.13–1.98) |
| Bilirubin [times ULN] | 0.48 (0.14–2.53) |